Dexamethasone in hyperleukocytic acute myeloid leukemia

Area of Science:

• Hematology
• Oncology
• Pharmacology

Background:

• Acute myeloid leukemia (AML) with high white blood cell counts presents a high risk of early mortality and disease relapse.
• Inflammatory mediators are implicated in leukostasis and chemoresistance in AML.
• Dexamethasone, a corticosteroid, may offer therapeutic benefits when combined with chemotherapy.

Purpose of the Study:

• To evaluate the impact of adding dexamethasone to standard chemotherapy in AML patients with hyperleukocytosis.
• To investigate the antileukemic activity and mechanisms of dexamethasone in AML.

Main Methods:

• Retrospective analysis of 160 AML patients (60 with dexamethasone, 100 without).
• In silico studies, primary patient samples, cell lines, and xenograft mouse models.
• Assessment of induction death, response rates, infections, relapse incidence, and survival outcomes.

Main Results:

• No significant differences in induction death, response, or infection rates between groups.
• Dexamethasone significantly improved relapse incidence, disease-free survival, event-free survival, and overall survival.
• Dexamethasone reduced leukemic stem cells, enhanced chemotherapy cytotoxicity, and modulated inflammatory pathways in chemoresistant cells.

Conclusions:

• Dexamethasone addition to chemotherapy may improve outcomes in AML patients with high white blood cell counts.
• The benefits may stem from modulating inflammatory chemoresistance pathways and specific activity in NPM1-mutated AML.
• Further prospective studies are warranted to confirm these findings.